CNSP (STOCKS)
CNS Pharmaceuticals, Inc. Common Stock
$3.640000
-0.450000 (-11.00%)
Prev close: $4.090000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Rami Levin
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2.25M
- Employees
- 4
- P/E (TTM)
- -0.06
- P/B (TTM)
- 0.24
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-5.76 | $-7.24 | +1.4769 | +20.41% |
|
Jun 2025 (Q2)
|
$-6.42 | $-9.79 | +3.3720 | +34.44% |
|
Dec 2024 (Q4)
|
$-111.00 | $-118.24 | +7.2384 | +6.12% |
|
Sep 2024 (Q3)
|
$-150.00 | $-61.20 | -88.8000 | -145.10% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $129.35K |
| Operating Expenses | $13.20M |
| Research and Development | $8.10M |
| Other Operating Expenses | $5.10M |
| Operating Income/Loss | -$13.20M |
| Income/Loss From Continuing Operations After Tax | -$13.07M |
| Income/Loss From Continuing Operations Before Tax | -$13.07M |
| Net Income/Loss | -$13.07M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$13.07M |
| Net Income/Loss Available To Common Stockholders, Basic | -$13.07M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $863.29 |
| Diluted Earnings Per Share | $863.29 |
| Basic Average Shares | 756,198 |
| Diluted Average Shares | 756,198 |
| Assets | $11.87M |
| Current Assets | $11.39M |
| Noncurrent Assets | $477.52K |
| Fixed Assets | $3.11K |
| Non-current Prepaid Expenses | $474.42K |
| Liabilities | $1.96M |
| Current Liabilities | $1.96M |
| Noncurrent Liabilities | $0.00 |
| Equity | $9.91M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $9.91M |
| Liabilities And Equity | $11.87M |
| Net Cash Flow From Operating Activities | -$16.23M |
| Net Cash Flow From Operating Activities, Continuing | -$16.23M |
| Net Cash Flow From Investing Activities | $3.02M |
| Net Cash Flow From Investing Activities, Continuing | $3.02M |
| Net Cash Flow From Financing Activities | $19.13M |
| Net Cash Flow From Financing Activities, Continuing | $19.13M |
| Net Cash Flow | $5.91M |
| Net Cash Flow, Continuing | $5.91M |
| Comprehensive Income/Loss | -$13.07M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$13.07M |
| Other Comprehensive Income/Loss | $0.00 |